As Amvuttra makes inroads in ATTR, Alnylam scraps heart disease trial interim analysis

Readout for newly FDA-approved Amvuttra in a rare heart disease is on many Alnylam investors’ mind. But the company figures patience is a virtue...

Recent Posts

The proposed expansion to the Inflation Reduction Act would substantially harm U.S. biopharma, triggering hundreds of thousands of job...

Pharmaceutical companies are delaying, or outright canceling, the development of new medicines following new drug rules signed into law...

The passage of last year’s Inflation Reduction Act (IRA) made major structural changes to the way Medicare covers and pays for...